Scientists find blood-based biomarkers for inflammatory breast cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 04:16 ET (22-Jun-2026 08:16 GMT/UTC)
How does the innate immune system distinguish pathogens from self-components while avoiding excessive immune response and inflammation? Toll-like receptors (TLRs) have provided the answer to this central question over four decades of research. This review synthesizes the multilayered and interactive regulatory mechanisms—from post-translational modifications to phase separation—that ensure balanced TLR signaling, and explores the translational promise of targeting these pathways in infectious diseases, autoimmune diseases, cancer, and inflammatory aging.
A multicenter study found that the advanced lung cancer inflammation index (ALI) predicts outcomes in acute ischemic stroke patients receiving thrombolysis. Lower ALI levels were strongly linked to poorer functional recovery, with a non-linear J-shaped relationship and a threshold effect. Derived from routine clinical measures, ALI offers a simple, accessible biomarker for early risk stratification.
How cells precisely control the timing of mRNA activation during differentiation is a longstanding question in molecular biology. In this study, researchers uncovered the MX-H pathway and MXL vesicles as the machinery responsible for removing inhibitory RNA-binding proteins and unleashing stored mRNAs at the right moment for sperm maturation. Importantly, the team found that this germ cell-specific system is hijacked by gastric cancer to promote tumor growth. These findings not only illuminate a fundamental regulatory mechanism in development but also identify a promising new target for selective cancer therapy.
New research shows that the same genes are active in pancreatic cancer, obesity and diabetes, helping to explain why people with metabolic disease often face poorer cancer outcomes and pointing to future ways to predict recurrence and develop more targeted treatments.
The UK‑led OpenBind initiative has reached a major milestone with the release of its first publicly available dataset , a groundbreaking step toward accelerating the discovery of new medicines using artificial intelligence. The release makes high‑quality, standardised experimental data freely accessible to researchers worldwide, providing AI-ready data to address the most persistent barriers in AI‑driven therapeutic development.
First-line therapy has strong response rates in patients with advanced lung cancer
Clinical studies show promising treatment results for lymphoma and AML
Researchers gain new insights into mechanisms of infertility and cancer progression
Novel tools used to predict risk of genetic mutations and for imaging of DNA stress